To all our CKB CORE users, don’t miss the latest new features now available! Register for a free CORE account here and then login for access. Feel free to contact us at ckbsupport@genomenon.com if you have any questions!

Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT06015880
Title Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
City of Hope Comprehensive Cancer Center LAO RECRUITING Duarte California 91010 United States Details
City of Hope Comprehensive Cancer Center RECRUITING Duarte California 91010 United States Details
University of California Davis Comprehensive Cancer Center RECRUITING Sacramento California 95817 United States Details
Moffitt Cancer Center RECRUITING Tampa Florida 33612 United States Details
Northwestern University RECRUITING Chicago Illinois 60611 United States Details
Wake Forest University Health Sciences RECRUITING Winston-Salem North Carolina 27157 United States Details
University of Oklahoma Health Sciences Center RECRUITING Oklahoma City Oklahoma 73104 United States Details
University of Virginia Cancer Center RECRUITING Charlottesville Virginia 22908 United States Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field